Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/2003
04/17/2003WO2003031628A1 Secretory polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
04/17/2003WO2003031627A1 Platelet-origin polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same
04/17/2003WO2003031615A1 Lysophosphatidic acid synthase inhibitor
04/17/2003WO2003031466A2 Angiotensin peptide-carrier conjugates and uses thereof
04/17/2003WO2003031459A2 Modulation of the expression of genes dependent on stat-1
04/17/2003WO2003031448A1 Reverse-turn mimetics and method relating thereto
04/17/2003WO2003031447A2 Pyrimidine derivatives
04/17/2003WO2003031445A1 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
04/17/2003WO2003031442A1 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
04/17/2003WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003WO2003031436A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract
04/17/2003WO2003031434A1 Compounds and methods
04/17/2003WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
04/17/2003WO2003031431A1 Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
04/17/2003WO2003031415A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
04/17/2003WO2003031414A1 Novel heterocyclic compound and anti-inflammatory agent
04/17/2003WO2003031408A2 Tricyclic compounds useful for modulating lxr
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003031405A2 Methods for the synthesis of substituted purines
04/17/2003WO2003031404A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
04/17/2003WO2003031396A1 Salts of guanidine derivatives and pharmaceutical preparations consisting thereof
04/17/2003WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030942A1 Pharmaceutical formulation
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030930A1 Human 3 relaxin
04/17/2003WO2003030925A1 Angiogenesis drugs
04/17/2003WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
04/17/2003WO2003030904A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030891A1 Use of hydroxyoleic acid and similar compounds in the production of medicaments
04/17/2003WO2003030889A1 Para-amino benzoic acids as integrin antagonists
04/17/2003WO2003030885A2 Modulation of the adventitial tool-like receptor
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030875A1 Over-coated chewing gum formulations including tableted center
04/17/2003WO2003030867A2 Method for preparing an interactive compound of an anilide derivative with a porous support by supercritical fluid
04/17/2003WO2003030833A2 Angiopoietin-2 specific binding agents
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003014315A3 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
04/17/2003WO2003008457A3 Polysaccharidic esters of retinoic acid
04/17/2003WO2003007922A3 Pharmaceutical formulation containing an ltb4 antagonist
04/17/2003WO2003005999A3 Methods of treating cytokine mediated diseases
04/17/2003WO2002098852A3 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
04/17/2003WO2002079221A3 Sapogenin derivatives, their synthesis and use
04/17/2003WO2002076486A3 Histidine-rich glycoprotein
04/17/2003WO2002072636A3 Crystals of whole antibodies and fragments thereof and methods for making and using them
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002058718A3 Use of compositions containing pdgf-bb for promoting angiogenesis
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002050284A3 Oxidoreductases
04/17/2003WO2002033094A1 Antibody inhibiting vplf activity
04/17/2003WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
04/17/2003WO2002032445A3 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018575A3 Genes expressed in the cell cycle
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2001078709A3 Treatment of neurodegenerative disease
04/17/2003WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
04/17/2003WO2001072752A3 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003WO1999056766A3 Method for treating ischemia
04/17/2003US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
04/17/2003US20030073846 Aminoalcohol derivatives
04/17/2003US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
04/17/2003US20030073833 Antiinflammatory agents; anticoagulants
04/17/2003US20030073733 Pharmaceutically active compounds and methods of use
04/17/2003US20030073732 Antiinflammatory agents
04/17/2003US20030073729 Medicaments for diabetic complication and neuropathy, and uses thereof
04/17/2003US20030073727 Central nervous system disorders
04/17/2003US20030073724 Central nervous system disorders
04/17/2003US20030073723 Antiinflammatory agents; rheumatic diseases; antiallergens
04/17/2003US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease
04/17/2003US20030073715 Nasal administering; side effect reduction
04/17/2003US20030073712 Antiinflamamtory agents; antiischemic agents
04/17/2003US20030073710 Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor
04/17/2003US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents
04/17/2003US20030073699 Compounds and methods to treat cardiac failure and other disorders
04/17/2003US20030073692 Anticancer agents; viricides; Alzheimer's diseases
04/17/2003US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents
04/17/2003US20030073684 Respiratory system disorders; cardiovascular disorders; hemorrhage therapy
04/17/2003US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
04/17/2003US20030073671 Side effect reduction; hormone replacement therapy
04/17/2003US20030073670 Aqueous solution
04/17/2003US20030073669 N-heterocyclic derivatives as NOS inhibitors
04/17/2003US20030073218 Enzyme inhibitor for us in the treatment and prevention of tumors
04/17/2003US20030073167 DNA encoding SNORF36 receptors
04/17/2003US20030073118 MID 9002, a human sulfatase family member and uses therefor
04/17/2003US20030073076 Analyzing modulators or treatments of fibroproliferative diseases; obtain sample, incubate with modulator, monitor marker expression, decreased expression indicate effective modulator
04/17/2003US20030072822 Methods for treating disorders using plant extracts
04/17/2003US20030072818 For inhibiting platelet aggregation, for prolonging bleeding time
04/17/2003US20030072808 Immediate release eplerenone compositions
04/17/2003US20030072763 Absorb in the low- energy, ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum that are used for the phototherapy of tumors and other lesions
04/17/2003US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
04/17/2003US20030072736 Human tumor necrosis factor receptor TR16
04/17/2003CA2464662A1 Modulation of the expression of genes dependent on stat-1
04/17/2003CA2463507A1 Methods for the synthesis of substituted purines
1 ... 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 ... 1595